BiotechTube

BGG492

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adrenocortical Adenoma

Conditions

Adrenocortical Adenoma, Endometrial Stromal Sarcomas

Trial Timeline

Aug 1, 2014 → Sep 1, 2015

NCT ID
NCT02150213

About BGG492

BGG492 is a phase 2 stage product being developed by Novartis for Adrenocortical Adenoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02150213. Target conditions include Adrenocortical Adenoma, Endometrial Stromal Sarcomas.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02150213Phase 2Completed
NCT01338805Phase 2Completed

Competing Products

6 competing products in Adrenocortical Adenoma

See all competitors
ProductCompanyStageHype Score
DS9051bDaiichi SankyoPhase 1
33
OSI-906Astellas PharmaPhase 3
77
Iressa (ZD1839)AstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52
SunitinibPfizerPhase 2
51
Relacorilant + PembrolizumabCorcept TherapeuticsPhase 1
28

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85